Rheum - RA Flashcards

1
Q

RA?

A

Rheumatoid Arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Define RA

A

Chronic inflammatory condition characterised by
• PAIN
• STIFFNESS
&
• SYMMETRICAL SYNOVITIS (inflammation of synovial membrane) of synovial joints

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Key features of RA?

A

o Chronic arthritis
• Polyarthritis – swelling of small joints (hand/wrist)
• Symmetrical
• Early morning stiffness
• May lead to joint damage & destruction

o Extra-articular disease (may occur)
• Rheumatoid nodules – SC swellings (immune complexes and RF)

o Rheumatoid “factor” (Anti-IgG IgM-auto-antibody)
• IgM auto-Ab against IgG

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Epidemiology of RA?

A

1% of population affected

F:M = 3:1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Genetic component of RA?

A

Heritability estimates of up to 60%

The genetic component comes from a specific set of amino-acids in the beta-chain of the HLA-DR molecule
• this specific set is then shared amongst all RA HLA sub-sets – termed “Shared epitope”

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Environmental component of RA?

A

Smoking

• interacts with shared epitope to increase risk!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Most common affected joints of RA?

A
o	Metacarpophalangeal joints (MCP).
o	Proximal interphalangeal joints (PIP).
o	Wrists.
o	Knees.
o	Ankles.
o	Metatarsophalangeal joints (MTP).

My Poor Willy Knows All Mothers.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Features of RA?

A

SYMMETRICAL POLYARTHRITIS
• symmetrical!!

Swan-neck deformities
• affects ring-finger with HYPER-extension of PIP join
AND
• HYPER-flexion of DIP joint

Boutonniere deformity
• affects little finger with HYPER-flexion of PIP joint

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Where is the 1o site of pathology of RA?

A

In the SYNOVIUM, located at:

• Synovial joints - PIP joint synovitis

• Tenosynovium - extensor tenosynovitis
- tendons wrapped in Tenosynovium

• Bursa - olecranon bursa for e.g.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What then develops after the 1o site of pathology and explain this

A

Sub-cutaneous nodules!

Nodule structure:
• Central area – fibrinoid necrosis surrounded by macrophages
• Peripheral area – connective tissue

o Occur in ~30% patients.
o Associated with – severe RA, extra-articular manifestations, RF

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Explain the influence RF has on RA

A

RF - rheumatoid factor

These are Abs that recognise the Fc portion of IgG as their target antigen!
• typically IgM Abs i.e. IgM anti-IgG Abs

RF is present in 70% at disease onset and a further 10-15% become positive over the first 2 years of diagnosis

 Correlations:
o High RH alpha with likelihood of joint damage.
o High RH /alpha/ with how ill the patient feels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Explain the influence of ACPA on RA

A

ACPA - anti-cyclic citrullinated peptide Ab

Abs to citrullinated peptides are HIGHLY SPECIFIC for RA
• mediated by PADs (enzymes)
• PADs are MORE active at sites of inflammation when they are produced by neutrophils & monocytes

ACPA is strongly associated with:
• smoking (more citrullination in lungs)
• HLA - ‘shared epitope’

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Why might an individual be more susceptible to RA in regards to ACPA?

A

An individual may be susceptible if they carry the specific amino-acid sequence in their HLA-DR antigen-binding groove – “Shared epitope”

  • Shared sequence in amino-acids 70-74 of the HLA-DRbeta- chain
  • Hence, multiple serotypes of HLA are associated with RA (HLA-DR1, 4, 6, 10) – all have “Shared epitope”

This shared epitope preferentially binds non-polar substances such as CITRULLINE

Environmental factors can enhance levels of citrulline (e.g. smoking) so the cause of anti-CCP antibodies could be a combination of genetics and the environment.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Extra-articular features of RA - both common and uncommon?

A

Common:
 Pyrexia, weight loss
 SC nodules

Uncommon:
	Vasculitis
	Episcleritis – ocular inflammation
	Neuropathies
	Amyloidosis
	Lung disease – fibrosis, nodules
	Felty’s syndrome – (3) triad of – splenomegaly, leucopenia, RA
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Radiographic abnormalities of RA?

A

Early
• juxta-articular osteopenia (low bone density juxta-articular bone)

Later
• joint erosions at margins of joints

Later still
• joint deformity and destruction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What do you normally find in the synovial joint?

A

Synovium:
• 1-3 cells thin.
• Contains – type-A synoviocyte (phagocytic), type-B synoviocytes (produce hyaluronic acid) and T1 collagen

Synovial fluid:
• Hyaluronic acid

Articular cartilage:
• T2 collagen
• Proteoglycan – mainly aggrecan

17
Q

What happens to the synovial membrane in RA?

A

Synovium becomes a proliferated mass of tissue (pannus) due to:
 Neovascularisation.
 Lymphangiogenesis.
 Inflammatory cells – B/T-cells, plasma cells, mast cells and activated macrophages

  • Due to excess, pro-inflammatory cytokine imbalance.
  • Mainly due to actions of TNF-a.
  • Therapy for RA – TNF-a can be inhibited by SC antibodies/fusion proteins.
18
Q

Pathology of RA?

A

In rheumatoid arthritis, the synovial membrane becomes thickened and chronically inflamed
• It will also cause joint swelling, which is referred to pathologically as a pannus (synovial tissue that is chronically inflamed)

The inflammation then starts to eat away at adjacent bone
•There is a small area of bone that is within the synovial membrane but is notcovered by articular cartilage - this bare area of bone is often where erosion is first seen (because the pannus normally has to destroy the cartilage before it reaches the bone) -­‐periarticular erosionsare seen first

Eventually there will be cartilage damage -­‐this is very difficult to reverse

19
Q

What is the basis of biological therapy often given to people with RA?

A

Alongside TNF-a:
• IL-6 and IL-1 can also be blockaded

We can also deplete B-cells in RA by IV anti-CD20 antibodies
o Rituximab

20
Q

What is the treatment goal for RA?

A

To PREVENT DAMAGE

21
Q

How is the treatment goal for RA achieved?

A

Multidisciplinary approach
• physio, occupational therapy, hydrotherapy, surgery

Medication including:

• Drugs – DMARDs – Disease-Modifying Anti-Rheumatic Drugs.

  • Started early in the disease – joint destruction = inflammation x time
  • DMARDs (“steroid-sparing agents”) are safer and more effective in the long term than steroids since they avoid the long-term side-effects of steroids

• Biological therapy

• Glucocorticoid therapy – e.g. prednisolone.
- Avoid long-term use due to side-effects but useful in the short-term to relieve symptoms.

22
Q

DMARDs?

A

Disease-Modifying Anti-Rheumatic Drugs

Drugs that
• INDUCE REMISSION (NOT cure)
&
• PREVENT joint damage

23
Q

How do DMARDs fulfil their functions?

A

They do this by
• reducing inflammation in synovium
&
• slowing/preventing structural joint damage

Complex mechanisms – SLOW ONSET

Examples – methotrexate, sulphasalazine, hydroxychloroquine (all commonly used)
• Leflunomide, gold and penicillamine (rarely used).
• Everything has significant side effects so require regular blood monitoring.

24
Q

What has changed about the biological therpaies over time?

A

The older biological therpaies were mouse Abs
• so WOULD trigger an IR
• e.g. Rituximab & Infliximab

The newer therpaies are completely human Abs
• so do NOT trigger at IR
• e.g. Adalimumab & Golimumab

25
Q

Downside of the biological therpaies on offer?

A

£££ & limited by NICE
- biological therapy involves ALL the Abs treatment SO methotrexate ( non-biological treatment) is used first

Side-effects from biological therapy includes an increased risk of infection

26
Q

Specifically, how do parts of biological therapy lead to downsides?

A

TNF-a inhibition
• increased susceptibility to mycobacterial infections (screen patients for TB)

B-cell depletion
• (can) to hepatitis B re-activation (so screen patients for Hep B)

B-cell depletion
• (can) to JC virus infection and progressive multi-focal leukoencephalopathy (PML)

27
Q

Which aspects does biological therapy work on?

A

Inhibition of TNF-alpha
• aka. anti-TNF

B-cell depletion

Modulation of T-cell co-stimulation

Inhibition of IL-6